Management of Rheumatoid Arthritis
Diagnosis and Early Referral
- The American College of Rheumatology recommends referring patients with suspected persistent synovitis urgently for specialist rheumatologist evaluation, even with normal acute-phase reactants or negative rheumatoid factor, especially when small joints of hands/feet are affected, multiple joints are involved, or symptoms have persisted for ≥3 months 2, 3
- The British Medical Journal suggests testing for rheumatoid factor in patients with suspected RA who have synovitis 4
- Consider measuring anti-cyclic citrullinated peptide antibodies in rheumatoid factor-negative patients, particularly when combination therapy is being considered, as recommended by the British Medical Journal 5
Treatment Principles
- The European League Against Rheumatism recommends that treatment should aim at reaching a target of remission or low disease activity as soon as possible in every patient 6
- Treatment should be adjusted through frequent monitoring (every 1-3 months) until the target is reached, according to the European League Against Rheumatism 6
- Rheumatologists should primarily care for patients with RA, with treatment decisions based on shared decision-making between patient and physician, as suggested by the European League Against Rheumatism 6
Pharmacologic Management
- Methotrexate (MTX) should be part of the first treatment strategy in patients with active RA, according to the European League Against Rheumatism 6
- The European League Against Rheumatism recommends starting MTX as soon as the diagnosis of RA is made 6
- When MTX is contraindicated or not tolerated, consider leflunomide, sulfasalazine, or injectable gold as alternative first-line DMARDs, as suggested by the European League Against Rheumatism 6
- Low to moderately high doses of glucocorticoids added to DMARD therapy provide benefit as initial short-term treatment, according to the European League Against Rheumatism 6
- The European League Against Rheumatism recommends tapering glucocorticoids as rapidly as clinically feasible 6
- If treatment target is not achieved with first DMARD strategy and poor prognostic factors are present, consider adding a biologic DMARD, as suggested by the European League Against Rheumatism 6
- Tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab) are typically the first biologic agents used, and should be combined with MTX, according to the European League Against Rheumatism 6
- If a first TNF inhibitor fails, consider another TNF inhibitor, abatacept, rituximab, or tocilizumab, as recommended by the European League Against Rheumatism 6
- For refractory severe RA or when biologics are contraindicated, consider azathioprine, cyclosporine A, or in exceptional cases, cyclophosphamide, as suggested by the European League Against Rheumatism 6
Monitoring and Treatment Adjustment
- Consider tapering biologic DMARDs in patients who achieve persistent remission, especially if combined with a synthetic DMARD, as recommended by the European League Against Rheumatism 6
- In cases of sustained long-term remission, cautious reduction of synthetic DMARD dosage may be considered, according to the European League Against Rheumatism 6
Non-Pharmacologic Management
- Patient education about disease pathophysiology, self-management skills, and joint protection principles improves health outcomes and physical function, as suggested by the Mayo Clinic Proceedings 7
- Occupational therapy provides benefits through joint protection instruction and prescription of assistive devices, orthotics, and splints, according to the Mayo Clinic Proceedings 7
- Dynamic exercise programs incorporating both aerobic exercise and progressive resistance training improve fitness and strength without exacerbating disease activity, as recommended by the Mayo Clinic Proceedings 7
- A multidisciplinary approach involving rheumatologists, nurses, physical and occupational therapists, and psychologists optimizes outcomes, according to the Mayo Clinic Proceedings 7